CompanyDrug

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations

CompanyDrug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
Company

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

CompanyDrug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

CompanyDeals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

CompanyMedical Device

Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit

CompanyDrug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
Company

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion
Company

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
Company

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
CompanyDeals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

CompanyDrug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial